Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120803 · ClinicalTrials.gov registry record · Phase 2
Esomeprazole and Radiation Induced Esophagitis
A Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06120803: Recruiting Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis, sponsored by Rush University Medical Center.
NCT06120803 is a Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06120803, a Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
Primary Outcome
The primary objective of this study is to determine the effect of esomeprazole on the frequency of acute symptomatic RE after thoracic radiotherapy (TRT) in a cohort of patients with locally advanced NSCLC treated with definitive TRT. Both clinician-reported metrics (CTCAE) and patient-reported metrics (Patient-Reported Outcomes version of the CTCAE) will be used.
Conditions Studied
Interventions
- DRUG Esomeprazole 40 mg
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT06120803 shows while recruiting
NCT06120803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Locally Advanced Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Esomeprazole 40 mg is the first listed.
NCT06120803 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06120803 about?
NCT06120803 is a clinical study titled "Esomeprazole and Radiation Induced Esophagitis". Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT06120803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-03-01. Estimated completion is 2028-06-30.
What conditions does trial NCT06120803 study?
This clinical trial studies the following conditions: Locally Advanced Lung Carcinoma, Radiation Esophagitis.
What interventions are being tested in trial NCT06120803?
The interventions under investigation include: Esomeprazole 40 mg (DRUG).
Who is sponsoring clinical trial NCT06120803?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120803 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06120803's enrollment target sits among peer trials
48 1265th of 2000 higher than 719 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI